[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 10",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list for the week of August 10, 2025 -- here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=d3328f7322da5e3893bf572815a85939fa978cabae6f64d3ced8fdd259c3dc94",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754676459,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 10",
      "id": 136273781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list for the week of August 10, 2025 -- here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=d3328f7322da5e3893bf572815a85939fa978cabae6f64d3ced8fdd259c3dc94"
    }
  },
  {
    "ts": null,
    "headline": "IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates",
    "summary": "Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.",
    "url": "https://finnhub.io/api/news?id=7e2e641e33b588a5eed937d0420dbe24720c611289cd1dc116781728a3345e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754663760,
      "headline": "IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates",
      "id": 136276265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.",
      "url": "https://finnhub.io/api/news?id=7e2e641e33b588a5eed937d0420dbe24720c611289cd1dc116781728a3345e4a"
    }
  },
  {
    "ts": null,
    "headline": "Epkinly breaks ground in Phase III FL trial",
    "summary": "While Epkinly is approved in third-line follicle lymphoma, its success in the second-line setting is pertinent.",
    "url": "https://finnhub.io/api/news?id=97017752e42c855d9f13fa7e3954b068eb37fec2a2910f4f0d78004da990dfb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754653804,
      "headline": "Epkinly breaks ground in Phase III FL trial",
      "id": 136266527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "While Epkinly is approved in third-line follicle lymphoma, its success in the second-line setting is pertinent.",
      "url": "https://finnhub.io/api/news?id=97017752e42c855d9f13fa7e3954b068eb37fec2a2910f4f0d78004da990dfb7"
    }
  }
]